99% Apixaban CAS 503612-47-3

Incazelo emfushane:

Igama lekhemikhali:I-Apixaban
Elinye igama:1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine -3-carboxaMide;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,
5-dihydropyrazolo[3,4-c]pyridine-3-carboxaMide
Inombolo ye-CAS:503612-47-3
Ubumsulwa:99%imizuzu
Ifomula:I-C25H25N5O4
Isisindo se-Molecular:459.50
Izakhiwo Zekhemikhali:I-Apixaban iyimpushana emhlophe ecwebezelayo.Iwuhlobo olusha lwe-oral Xa factor inhibitor, futhi igama layo lezentengiso i-Eliquis.I-Apixaban isetshenziselwa ukwelapha iziguli zabantu abadala ezihlinzwa ngokukhethwa kwe-hip noma idolo ukuze kuvinjelwe i-venous thromboembolism (VTE).

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Omaka bomkhiqizo

Ukucaciswa

INTO	IZINGA
Ukubukeka	Okuqinile okumhlophe kuya kokumhlophe
Ubumsulwa	≥ 99%

Isicelo

I-Apixaban iwuhlobo olusha lwe-anticoagulant yomlomo, uhlobo olusha lwe-oral factor Xa inhibitor, olusetshenziselwa ukuvimbela nokwelapha amahlule egazi.
I-Apixaban iyi-oral factor Xa inhibitor entsha eyakhiwe ngokuhlanganyela yiBristol-Myers Squibb kanye nePfizer.Ngokuvimbela i-coagulation factor ebalulekile Xa, i-apixaban ivimbela ukukhiqizwa kwe-thrombin kanye ne-thrombosis.

Ngomhla zingama-26 kuMbasa, 2007, iBristol-Myers Squibb kanye noPfizer bamemezele ukuthuthukiswa okuhlanganyelwe kwe-apixaban entsha ye-oral anticoagulant ephethwe yiBristol-Myers Squibb njengendlela ethuthukisiwe ye-warfarin.
Ngo-May 2011, i-apixaban yaba ngowokuqala ukugunyazwa ukuvimbela i-venous thrombosis ezigulini ezikhulile ezenza ukuhlinzwa okukhethiwe kwe-hip noma idolo emazweni e-27 EU, e-Iceland naseNorway.
Ngomhla ka-November 20, i-2012, i-European Commission yavuma i-ELIQUIS (apixaban) yokuvimbela isifo sohlangothi kanye ne-systemic embolism kubantu abadala abane-non-valvular atrial fibrillation (NVAF) enesici esisodwa noma ngaphezulu engozini.
I-Canadian Food and Drug Administration, Japan, kanye ne-US Food and Drug Administration yabe isigunyaza i-ELIQUIS (apixaban) yokuvimbela isifo sohlangothi kanye ne-systemic embolism kubantu abadala abane-non-valvular atrial fibrillation (NVAF) enesici esisodwa noma ngaphezulu engozini.
Ngo-Ephreli 12, 2013, i-ELIQUIS (Apixaban), imenyezelwe ngokusemthethweni emakethe eChina.I-Apixaban iyinoveli ye-oral factor Xa inhibitor yokuvimbela i-venous thromboembolism (VTE) ezigulini ezikhulile ezenza ukuhlinzwa okukhethiwe kwe-hip noma idolo.Ukwethulwa kwayo kunikeza inketho entsha ephephile nephumelelayo ye-anticoagulation ngemva kokuhlinzwa kwamathambo emisebenzini yomtholampilo, futhi kuletha izindaba ezinhle ezigulini zaseShayina ezishintshwa ngokukhethwa kwe-hip/knee.
Ucwaningo lwezokwelapha luye lwaqinisekisa ukuthi uma kuqhathaniswa nomjovo we-enoxaparin we-40 mg we-subcutaneous kanye ngosuku, i-2.5 mg ye-ELIQUIS (Apixaban) ngomlomo kabili ngosuku iphumelela kakhulu ekuvimbeleni izenzakalo ze-venous thromboembolic ngemva kokuhlinzwa esikhundleni se-hip noma idolo, futhi awanyusi ingozi yokugula. ukopha.